Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics (DE:0K4)
:0K4
0K4 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€16.77 - €55.10
Previous CloseN/A
Volume0.00
Average Volume (3M)131.00
Market Cap
€3.20B
Enterprise Value€1.31B
Total Cash (Recent Filing)$340.24M
Total Debt (Recent Filing)$36.46M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 20, 2025EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding79,620,125
10 Day Avg. Volume25
30 Day Avg. Volume131
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.30
Forecast
1Y Price Target
€67.85Price Target Upside76.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Akero Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive 96-week data from the Phase IIb SYMMETRY study in F4 cirrhotic MASH was recently reported.
Financial PositionAkero reported a cash position of $797.8M, showing financial stability.
Bears Say
Market CompetitionStrategic interest for Akero’s FGF21 analog remains high, particularly as large biopharma look to build out their respective MASH portfolios.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.55% Insiders
24.90% Mutual Funds
40.02% Other Institutional Investors
19.35% Public Companies and Individual Investors
0K4 FAQ
What was Akero Therapeutics’s price range in the past 12 months?
Akero Therapeutics lowest stock price was €16.77 and its highest was €55.10 in the past 12 months.
What is Akero Therapeutics’s market cap?
Akero Therapeutics’s market cap is €3.20B.
When is Akero Therapeutics’s upcoming earnings report date?
Akero Therapeutics’s upcoming earnings report date is May 20, 2025 which is in 69 days.
How were Akero Therapeutics’s earnings last quarter?
Akero Therapeutics released its earnings results on Feb 28, 2025. The company reported -€0.933 earnings per share for the quarter, beating the consensus estimate of -€1.094 by €0.161.
Is Akero Therapeutics overvalued?
According to Wall Street analysts Akero Therapeutics’s price is currently Undervalued.
Does Akero Therapeutics pay dividends?
Akero Therapeutics does not currently pay dividends.
What is Akero Therapeutics’s EPS estimate?
Akero Therapeutics’s EPS estimate is -0.93.
How many shares outstanding does Akero Therapeutics have?
Akero Therapeutics has 79,620,125 shares outstanding.
What happened to Akero Therapeutics’s price movement after its last earnings report?
Akero Therapeutics reported an EPS of -€0.933 in its last earnings report, beating expectations of -€1.094. Following the earnings report the stock price went up 1.127%.
Which hedge fund is a major shareholder of Akero Therapeutics?
Currently, no hedge funds are holding shares in DE:0K4
---
Akero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€67.85 (76.74% Upside)
€67.85 (76.74% Upside)
Blogger Sentiment
Bullish
DE:0K4 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $9.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.50%
12-Months-Change
Fundamentals
Return on Equity
-39.22%
Trailing 12-Months
Asset Growth
42.33%
Trailing 12-Months
Company Description
Akero Therapeutics
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Month Forecast
Average Price Target
€67.85
▲(76.74% Upside)
Technical Analysis
Conmed
―
Madrigal Pharmaceuticals
―
Galectin Therapeutics
―
RedHill Biopharma
―
Viking Therapeutics
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+45.51%
reiterated a buy rating 7 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +45.51% per trade.
---